New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 14, 2014
08:59 EDTYHOO, CVM, NBG, WBMD, ICPT, ACOR, LXRX, MDT, EW, FB, C, AKBAOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Citigroup (C), up 3.7%. ALSO HIGHER: Yahoo (YHOO), up 1.7% after upgraded to Buy from Neutral at SunTrust... Facebook (FB), up 2.5% after Financial Times reports company looking to provide financial services... Lexicon (LXRX), up 19.5% after achieving positive results in Type 1 diabetes clinical trial... Akebia (AKBA), up 13.8% after initiated at Nomura, Credit Suisse, Morgan Stanley and UBS... WebMD (WBMD), up 10% after saying it now sees Q1 adjusted EBITDA to come in above the high end of its previous guidance... Intercept (ICPT), up 4.9% after reporting additional data from POISE trial at EASL... Ewards Lifesciences (EW), up 11.3% after a district court granted a preliminary injunction limiting the sale of Medtronic's (MDT) CoreValve system in the U.S. Medtronic shares down 5.2% following the news. ALSO LOWER: National Bank of Greece (NBG), down 10.7% after Reuters says bank selected Goldman Sachs (GS) and Morgan Stanley (MS) as global coordinators for a planned equity offering... : CEL-SCI (CVM), down 10.6% after announcing intent to offer common stock, six month warrants in 'best efforts' offering... Acorda Therapeutics (ACOR), down 6.2% after pushing off start of Phase 3 study of dalfampridine-QD to second half of year.
News For YHOO;C;FB;EW;MDT;LXRX;ACOR;ICPT;WBMD;NBG;CVM;AKBA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | all recent news | >>
October 9, 2014
06:59 EDTFBFacebook has no imminent WhatsApp monetization goals, Reuters says
Subscribe for More Information
06:40 EDTCSource of JPMorgan cyberattack still unclear, NY Times says
The source of the cyberattack on JPMorgan (JPM) and other U.S. financial institutions this summer is still unclear, according to The New York Times. The hackers may have tried to hit about a dozen financial institutions , and E-Trade(ETFC) and Fidelity Investments may have been victimized in some way, the newspaper stated, citing an unnamed source who was briefed on the matter. At least five other banks, including Citigroup (C), HSBC (HBC) and Regions Financial (RF), discovered that one of the web addresses used by those who hacked JPMorgan tried to penetrate their systems, The Times quoted unnamed sources briefed on the matter as saying. Publicly traded companies in the space include Barracuda Networks (CUDA), Check Point (CHKP), F5 Networks (FFIV), FireEye (FEYE), Fortinet (FTNT), Imperva (IMPV), Palo Alto (PANW), Proofpoint (PFPT), Qualys (QLYS) and Symantec (SYMC). Reference Link
06:39 EDTCFidelity attacked by JPMorgan hackers, but no data stolen, FT reports
Fidelity Investments was among 13 financial institutions attacked by hackers who are believed to have been responsible for a breach at JPMorgan Chase, but there is no indication that Fidelity customer data were stolen, the Financial Times reports, citing two sources. Reference Link
06:37 EDTCJPMorgan hackers linked to 13 other possible breaches, Bloomberg says
Subscribe for More Information
06:35 EDTCCitigroup to return $16M to customers for fees on investment accounts, WSJ says
Subscribe for More Information
06:33 EDTCCitigroup 2015 consensus may be 10% too high, says Deutsche Bank
Deutsche Bank believes the IPO of OneMain, the consumer finance unit within Citi Holdings, and higher expenses create 10% risk to the 2015 consensus estimate of $5.40 for Citigroup. Deutsche says shedding OneMain would lower Citigroup's (C) annual earnings by about 20c. The firm says the bank's Q3 results could top expectations, however, on better than expected currency trading. Deutsche continues to prefer Bank of America (BAC) to Citi, saying its confident consensus estimates for the former are reasonable. It has a Hold rating on Citi and Buy rating on Bank of America.
October 8, 2014
18:26 EDTCCitigroup, Etrade, others attacked by same JPMorgan hackers, Bloomberg reports
Subscribe for More Information
16:01 EDTFBOptions Update; October 8, 2014
iPath S&P 500 VIX Short-Term Futures down 2.73 to 29.51. Option volume leaders: AAPL TSLA TWTR AMZN FB NFLX PBR AA CLF GILD according to Track Data.
12:42 EDTICPTIntercept weakness a buying opportunity, says Wedbush
Subscribe for More Information
12:11 EDTICPTIntercept management to meet with Oppenheimer
Subscribe for More Information
12:02 EDTCCitigroup's OneMain Financial preparing for $50M IPO, NY Times reports
Subscribe for More Information
09:38 EDTFBActive equity options trading on open
Subscribe for More Information
09:20 EDTICPTOn The Fly: Pre-market Movers
Subscribe for More Information
08:06 EDTCAstoria Financial appoints Hugh J. Donlon as Chief Lending Officer
Subscribe for More Information
07:24 EDTFBFacebook feature allows advertisers to find clients via location
Subscribe for More Information
07:19 EDTACORCBI to hold a conference
Subscribe for More Information
07:13 EDTCBank dealers agree to revised derivatives rules, FT reports
Subscribe for More Information
07:05 EDTICPTIntercept says FLINT trial NASH data will not be presented at AASLD
Intercept Pharmaceuticals announced upcoming presentations of data at the upcoming American Academy for the Study of Liver Diseases, or AASLD, Annual Meeting, being held in Boston, Massachusetts from November 7-11. Obeticholic acid, or OCA, Intercept's lead product candidate, is a bile acid analog and first-in-class agonist of the farnesoid X receptor in development for primary biliary cirrhosis, nonalcoholic steatohepatitis, primary sclerosing cholangitis and other chronic liver and intestinal diseases. CEO Mark Pruzanski said, "We are pleased that several key abstracts from Intercept's Phase 3 program for OCA in PBC will be presented at AASLD. With respect to the NIDDK-sponsored FLINT trial of OCA in NASH, we have learned that the NASH CRN has decided to focus on finalizing the manuscript intended for near term publication in lieu of presentation at AASLD. We are reaffirming the previously reported top-line results based on a revised draft manuscript that our partners at NIDDK have provided us. We believe that peer reviewed publication of the FLINT data will mark another important milestone supportive of OCA's potential as a novel therapy for patients with NASH and associated liver fibrosis. In the meantime, we continue preparing for the initiation of our Phase 3 NASH program in the first half of 2015."
06:19 EDTYHOOYahoo lays off 400 employees in India, WSJ reports
Subscribe for More Information
06:00 EDTFBInstagram still most used social network for teens, says Piper Jaffray
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use